ARA-290 Dosage Calculator & Doses

1Set Up Your Mix

5.333 mg/mL · 5333 mcg/mL

1. Pick your peptide

2. How much peptide is in the vial? It's printed on the label — usually something like 5 mg

3. How much water are you adding? More water makes each dose easier to measure

4. How much do you want per dose?

Your Answer — ARA-290

16 mg in 3 mL

37.5Draw To This Line

0.375That's This Many mL

8Doses In The Vial

16 mg ÷ 3 mL = 5.333 mg/mL → 2 mg ÷ 5.333 mg/mL = 0.375 mL → × 100 = 37.5 units

Looks good. Draw to 37.5 units on a 1 mL syringe. That is an easy amount to measure, and this vial gives you 8 doses.

When to dose

Time of dayNo particular time of day has been established.

FoodNo fasting requirement has been established.

The studies behind this compound did not test timing or food state, so we are not going to invent a rule.

2Week-By-Week Plan — ARA-290

Start low, work up

When	Dose	How Often	How Many mL	Draw To	Number Of Doses	Peptide Used
Weeks 1–2	2 mg	daily	0.375 mL	37.5 u	14	28 mg
Week 3 onward per 4 weeks from here on	4 mg	daily	0.75 mL	75 u	28	112 mg

Time until the top dose

2 weeks

Peptide used getting there

28 mg

Vials you'll need

2 × 16 mg

Once you're at the top dose

112 mg / 4 wk · 7 vials

Where this plan came from

Built from this peptide's dose range

Where this came from: Built from the doses listed for this peptide below — start at the lowest and step up, using the studies cited on this page. Nobody publishes a week-by-week plan for this peptide, so we built one: the doses are the researched ones shown below, and we simply put them in order from lowest to highest. Treat it as a starting point, not an official schedule.

3Common Doses — ARA-290

worked out for your mix

Level	Dose	How Often	How Many mL	Draw To	Doses In Vial
Trial dose	4 mg	daily ×28 days	0.75 mL	75 u	4 doses
Trial dose	2 mg	daily	0.375 mL	37.5 u	8 doses
Extended	4 mg	daily, longer courses	0.75 mL	75 u	4 doses

Please read this. These numbers come from published research. They are here as reference, not as instructions. A lot of them come from lab studies rather than studies in people, and some of these peptides have never been given to a person at all.

About ARA-290

Cognitive & Neuro

Also known as

Cibinetide, EPO helix-B surface peptide

Class

Cognitive & Neuro

Route

Subcutaneous

Half-life

~2 min (tissue effect far longer)

Evidence tier

Clinical

An 11-amino-acid erythropoietin derivative that engages the innate repair receptor without the erythropoietic or thrombotic effects of EPO. Studied in sarcoidosis-associated small fibre neuropathy and diabetic neuropathy with genuine registered trials.

Buy ARA-290

Research Equipment

SyringesU-100 insulin · 1 mL · 29–31G

Alcohol wipes70% isopropyl prep pads

Serum base — for topical mixesHyaluronic acid serum for mixing peptides into a serum

Electric cooler caseTSA-approved travel cooler — keeps mixed vials at fridge temperature

Storage caseHard carry case for vials

Paid affiliate links.

Common Questions — ARA-290

How much bacteriostatic water do I add to a 16 mg vial of ARA-290?

Adding 3 mL of bacteriostatic water to a 16 mg vial gives 5.33 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.

What dose of ARA-290 is used in research?

Published and reported figures for ARA-290 run from 2 mg to 4 mg, typically daily. This site lists each figure with the source it came from rather than giving a single recommended number.

How many units on the syringe is a 4 mg dose of ARA-290?

At 5.33 mg/mL, a 4 mg dose is 75 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 4 doses.

How strong is the evidence behind these ARA-290 doses?

ARA-290 is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.

Where These Numbers Come From

Clinical — Human trial or approved-label dosing published

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fibre loss Dahan A, et al. Molecular Medicine, 2013

The primary randomised human trial; source of the 4 mg daily figure.

Find on PubMed ↗

Erythropoietin-derived non-erythropoietic peptides and tissue protection Brines M, Cerami A. Journal of Internal Medicine, 2008

Mechanistic basis — the innate repair receptor concept.

Find on PubMed ↗

Newest Studies — —

—

Not reviewed by us. This list is pulled straight from Europe PMC as papers are published. Nobody has checked whether these are any good, or whether they change anything above. The dose numbers on this page only ever change after a person reviews the evidence.

ARA-290 Dosage & Reconstitution